Skip to main content

What the FDA labels say about taking them together

Letermovir and repaglinide

Letermovir's FDA label of January 14, 2026 names repaglinide in its drug interactions section; the repaglinide label PlainMeds reads does not name letermovir. The letermovir label: “When PREVYMIS is co-administered with glyburide, repaglinide, or rosiglitazone, frequently monitor glucose concentrations. When PREVYMIS is co-administered with cyclosporine, use of repaglinide is not recommended.”

Check it at the source: the letermovir FDA label on DailyMed (effective January 14, 2026, Merck Sharp & Dohme LLC); the repaglinide FDA label on DailyMed (effective May 2, 2025, Chartwell RX, LLC).

What does the letermovir label say about repaglinide?

Letermovir label, drug interactions

Concomitant Drug Class and/or Clearance Pathway/Drug Name: Examples: glyburide, repaglinide, rosiglitazone; Effect on Concentration ↓ =decrease, ↑ =increase: ↑ glyburide ↑ repaglinide ↑ rosiglitazone; Clinical Comments: When PREVYMIS is co-administered with glyburide, repaglinide, or rosiglitazone, frequently monitor glucose concentrations. When PREVYMIS is co-administered with cyclosporine, use of repaglinide is not recommended.

Source: FDA drug label (PREVYMIS), Merck Sharp & Dohme LLC, effective January 14, 2026 (SPL set 1b49df80-be4f-47e0-a0b7-123f3e69395b), via openFDA; the full label on DailyMed

What does the repaglinide label say about letermovir?

Repaglinide's label (effective May 2, 2025) does not name letermovir in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Repaglinide), Chartwell RX, LLC, effective May 2, 2025 (SPL set cb995e92-295e-4638-a064-978211f5afe1), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Letermovir generic labelers
7Repaglinide generic labelers
LetermovirRepaglinide
Labeled forn/aType 2 diabetes
Boxed warningNoNo
Pharmacy cost (NADAC)n/a$0.0987 per tablet 1 mg tablet
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?